NEPTUNE, N.J.--(BUSINESS WIRE)--SCIENTIFIC AMERICAN custom media is hosting a high-level panel forum to address the national opioid addiction epidemic and the stigma associated with a disease that kills more than 70 Americans each day. Panelists will provide insight on the pressing need to transform the way society addresses opioid addiction. Perspectives from government, criminal justice, the medical community and industry will be discussed.
This timely event embodies a growing movement calling for greater public policy understanding and insight on the topic, including those measures announced earlier this year by the White House at the National Rx Drug Abuse and Heroin Summit. The event will cover a wide range of new public policy initiatives and innovative treatment solutions informed by recent scientific evidence recognizing a genetic predisposition to opioid addiction. Urgent action is needed to help individuals in recovery, their families, medical professionals and law enforcement more effectively address opioid and heroin addiction as it continues to claim the lives of Americans each year at an alarming and increasing rate.
The group of distinguished panelists will include Governor Chris Christie, State of New Jersey, Leonard Campanello, Chief of Police, Gloucester, Massachusetts, Andrea Barthwell, MD, Former Deputy Director for Demand Reduction, Office of National Drug Control Policy, Addiction Specialist, and Behshad Sheldon, Chief Executive Officer, Braeburn Pharmaceuticals. The panel event will be moderated by Jeremy A. Abbate, Vice President & Publisher, Scientific American and Mike May, Editor, Scientific American Custom Media.
Organizers seek the participation of the medical community, policy makers, academia, and the media. The event will take place Thursday, May 19th, 2016, 11:00 AM - 12:30 PM ET, at the Jersey Shore University Medical Center, Lance Auditorium, 1945 New Jersey 33, Neptune City, NJ 07753.
Forum will be available via satellite: satellite test 10:00-11:00 am, Forum 11:00 AM to 12:30 PM
|GALAXY 16 / 17 Slot 3||Downlink: 12037 (Horizontal)||Symbol Rate: 4.0||FEC: 3/4|
|DVBS-2||8PSK||Pilot: OFF||Roll Off: 25%|
To RSVP for the event or for more information about this topic, please contact Susan Battafarano at 215 497-3188 or email at email@example.com.
About Braeburn Pharmaceuticals
Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn’s New Drug Application for its lead candidate, Probuphine®, a six-month buprenorphine implant for treatment of opioid addiction. The Agency set May 27, 2016 as the target date for action. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. Braeburn’s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Candidates include: Probuphine®, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia. More information on Braeburn, can be found at www.braeburnpharma.com.
About Scientific American Custom Media
SCIENTIFIC AMERICAN’s Custom Media Division, operating as a separate and distinct unit from its Editorial department, develops events, content, and special projects in partnership with corporations, government institutions and academia.